Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis.
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
Fingolimod modulates microglial activation to augment markers of remyelination.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
White matter astrocytes in health and disease.
The delta-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation.
Demyelination affects temporal aspects of perception: An optic neuritis study.
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Identification of the LDL Receptor-Related Protein-1 Interactome in Central Nervous System myelin suggests a role in the clearance of necrotic cell debris.
Amiloride HCl
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.
Pages
« first
‹ previous
…
93
94
95
96
97
98
99
100
101
…
next ›
last »